Elucirem patents expiration

ELUCIREM's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8114863 GUERBET Compounds comprising short aminoalcohol chains and metal complexes for medical imaging
Sep, 2028

(4 years from now)

US10973934 GUERBET Gadolinium bearing PCTA-based contrast agents
Aug, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590246 GUERBET Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
Jan, 2040

(16 years from now)

Elucirem is owned by Guerbet.

Elucirem contains Gadopiclenol.

Elucirem has a total of 3 drug patents out of which 0 drug patents have expired.

Elucirem was authorised for market use on 21 September, 2022.

Elucirem is available in solution;intravenous dosage forms.

Drug patent challenges can be filed against Elucirem from 2026-09-21.

The generics of Elucirem are possible to be released after 17 January, 2040.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 21, 2027

Drugs and Companies using GADOPICLENOL ingredient

NCE-1 date: 2026-09-21

Market Authorisation Date: 21 September, 2022

Treatment: NA


More Information on Dosage

ELUCIREM family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic